The world’s first malaria vaccine could be available in as little as three years after British drugmaker GlaxoSmithKline’s candidate treatment passed a major testing milestone

GSK malaria vaccine could be available in three years

The world’s first malaria vaccine could be available in as little as three years after British drugmaker GlaxoSmithKline’s candidate treatment passed a major testing milestone.

By Denise Roland

12:01AM BST 08 Oct 2013

GSK is ready to take the first step in getting the vaccine to market after promising trial results showing it was effective in protecting children and babies from malaria for up to 18 months. The pharmaceuticals giant plans to submit the vaccine to EU regulators next year, which means, if approved, it could be widely available by 2016. The World Health Organisation has already indicated that a policy recommendation for the vaccine, the most advanced treatment anywhere in the world by at least 10 years, could be made by 2015 if it clears regulatory hurdles.GSK scientists have spent nearly three decades developing a vaccine against malaria, one of the world’s deadliest diseases.

The vaccine has faced a number of setbacks during final-stage testing, but GSK and its partners believe the treatment has proven effective enough to make a “significant impact” on the health of millions of young children in Africa.

The latest results, unveiled today , show that the vaccine nearly halves the number of malaria cases in children between five and 17 months old for at least 18 months following the initial shot.

Earlier results, released in March, showed that the effectiveness of the vaccine wanes over time, protecting only 16.8pc of children for as long as four years.

Sir Andrew Witty, chief executive of GSK, said: “While we have seen some decline in vaccine efficacy over time, the sheer number of children affected by malaria means that the number of cases of the disease the vaccine can help prevent is impressive.”

Malaria experts agree that the vaccine has proven itself to be an effective weapon against malaria, but warn that unless it is provided cheaply enough, some low-income countries, dependent on aid from NGOs and charitable foundations, could be prevented from accessing it.

GSK is running its malaria programme as a non-profit operation, but has not yet disclosed how much it will cost to make the vaccine.

About bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (www.heroinnovator.com), the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: